Accelerated Approval
![FDA states that LN-145 in NSCLC is likely to receive accelerated approval](https://pharmtales.com/wp-content/uploads/2023/07/FDA-states-that-LN-145-in-NSCLC-is-likely-to-receive-accelerated-approval.jpg)
FDA states that LN-145 in NSCLC is likely to receive accelerated approval
SG Tylor
Source – Iovance Biotherapeutics The Phase II IOV-LUN-202 trial of LN-145 in patients with post-anti-PD-1 non-small cell lung cancer (NSCLC) ...